4-chlorothieno[3,2-d]pyridine | 477874-92-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: 4-chlorothieno[3,2-d]pyridine
• 英文别名: 4-chlorothieno[2,3-c]pyridine
• CAS: 477874-92-3
• 化学式: C₇H₄ClNS
• mdl: MFCD10699426
• 分子量: 169.634
• InChiKey: TZJPQRUHOWOSFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chlorothieno[3,2-d]pyridine 在 palladium on activated charcoal sodium hydroxide 、 N-碘代丁二酰亚胺 、 D(+)-10-樟脑磺酸 、 氢气 、 sodium hydride 、 碳酸氢钠 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 、 lithium hexamethyldisilazane 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 生成
  参考文献：
  名称：

  Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus

  摘要：

  Efforts directed to identifying potent HIV protease inhibitors (PI) have yielded a class of compounds that are not only very active against wild-type (NL4-3) HIV virus but also very potent against a panel of PI-resistant viral isolates. Chemistry and biology are described. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.072
• 作为产物：
  描述：

  4-三氟甲基-2-羟基嘧啶-5-羧酸 以 二苯醚 为溶剂， 反应 20.0h， 以88%的产率得到4-chlorothieno[3,2-d]pyridine
  参考文献：
  名称：

  A facile and general synthesis of 2,4‐Di‐ and 2,4,7‐trisubstituted thieno[2,3‐c]pyridines

  摘要：

  Abstractmagnified imageTreatment of 3,5‐dibromo‐ or 3,5‐dichloro‐pyridine‐4‐carboxaldehyde 2 with one equivalent of methyl thioglycolate, followed by exposure to base, provided 4‐bromo‐ or 4‐chloro‐thieno[2,3‐c]pyridine‐2‐carboxylate 4 in good yields. Oxidation of the thieno[2,3‐c]pyridine scaffold such as 7 with mCPBA, followed by treatment with POBr3, introduced a bromine exclusively at the 7‐position of the heterocycle. The 4‐ or 7‐bromide of the thienopyridines readily underwent Suzuki, Stille coupling, and Buchwald amination reactions, to afford 4‐ or 7‐substituted analogs 6 or 11. The 2‐carboxylate of 4b or 12 was smoothly removed through saponification and decarboxylation to furnish 15 or 16. Deprotonation of the thienopyridine at C‐2 position, followed by trapping with trimethyltin chloride, afforded a 2‐stannyl analog, which was readily converted to other C‐2 derivatives via Stille reaction.

  DOI：

  10.1002/jhet.5570450106

文献信息

• [EN] FUSED PYRIDINE AND PYRAZINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS CONDENSÉS DE PYRIDINE ET DE PYRAZINE EN TANT QU'INHIBITEURS DE KINASES
  申请人：UCB PHARMA SA

  公开号：WO2010092340A1

  公开（公告）日：2010-08-19

  A series of amino-substituted fused pyridine and pyrazine derivatives, in particular amino-substituted quinoline and quinoxaline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

  一系列氨基取代的融合吡啶和吡嗪衍生物，特别是氨基取代的喹啉和喹喔啉衍生物，作为选择性PI3激酶酶抑制剂，在医学上具有益处，例如在治疗炎症性、自身免疫性、心血管、神经退行性、代谢性、肿瘤学、疼痛性或眼科疾病方面。
• Kinase inhibitors
  申请人：——

  公开号：US20030187026A1

  公开（公告）日：2003-10-02

  Compounds having the formula 1 are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.

  具有以下化学式的化合物对抑制蛋白激酶很有用。还公开了抑制蛋白激酶的组合物以及在患者中抑制蛋白激酶的方法。
• Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
  申请人：Pfizer Inc.

  公开号：US06492383B1

  公开（公告）日：2002-12-10

  The invention relates to compounds of the formulas 1 and 2 and to pharmaceutically acceptable salts and hydrates thereof, wherein X1, R1, R2 and R11 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formulas 1 and 2 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formulas 1 and 2.

  本发明涉及式1和式2的化合物以及其药学上可接受的盐和溶剂合物，其中X1、R1、R2和R11如本文所定义。本发明还涉及包含式1和式2化合物的药物组合物，以及通过施用式1和式2的化合物治疗哺乳动物的过度增殖性疾病的方法。
• [EN] QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLÉINE ET DE QUINOXALINE EN TANT QU'INHIBITEURS DE KINASE
  申请人：UCB PHARMA SA

  公开号：WO2011058110A1

  公开（公告）日：2011-05-19

  A series of quinoline and quinoxaline derivatives, substituted by a fused bicyclic pyridine or pyrimidine moiety attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

  一系列喹啉和喹喔啉衍生物，通过一个融合的双环吡啶或嘧啶基团取代，并通过一个可选择连接到杂原子的烷基链，是选择性P13激酶酶抑制剂，在医学上具有益处，例如在炎症、自身免疫、心血管、神经退行性、代谢、肿瘤、疼痛或眼科疾病的治疗中。
• Thiophene derivatives useful as anticancer agents
  申请人：——

  公开号：US20020004511A1

  公开（公告）日：2002-01-10

  The invention relates to compounds of the formula 1 1 and to pharmaceutically acceptable salts and hydrates thereof, wherein X, Y, R 1 , R 2 and R 11 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula 1.

  该发明涉及公式11的化合物，以及其在药学上可接受的盐和水合物，其中X、Y、R1、R2和R11如本文所定义。该发明还涉及含有公式1化合物的药物组合物，以及通过给哺乳动物施用公式1化合物来治疗过度增殖性疾病的方法。